Dr. Yuan Zhang is currently an associate senior physician of Radiation Oncology in Sun Yat-sen University Cancer Center, State KeyLaboratory of Oncology in South China, Guangzhou, China. She has been dedicated to the clinical and translational research of Nasopharyngeal carcinoma (NPC) for over ten years. Her work includes a phase 3 trial demonstrating the efficacy of induction gemcitabine and cisplatin induction chemotherapy in locoregionally-advanced NPC (NEJM, 2021). This has been accepted as standard of care by guidelines such as NCCN, ESMO and CSCO. The combination of chemotherapy and radiotherapy, Nasopharyngeal Carcinoma, Head and Neck Cancer MD Zhongshan School of Medicine, Sun Yat-sen University (2013)
MS Sun Yat-sen University Cancer Center, Oncology (2016)
PhD Sun Yat-sen University Cancer Center, Oncology (2019)

1. Zhang Y# (first author), et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019; 381(12):1124-1135.  

2. Zhang Y#  (first author), et al. Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial. J Clin Oncol. 2022; 40(22):2420-2425.  

3. Liu X# , Zhang Y# (joint first author), et al. Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years. JAMA Oncol. 2018; 4(8):1073-1079.

4. Zhang Y#  (first author), et al. Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma. Cancer Commun (Lond). 2019; 39(1):39.  

5. Zhang Y#  (first author), et al. Spontaneous remission of residual post-therapy plasma Epstein-Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis. Int J Cancer. 2019; 144(9):2313-2319.  

6. Zhang Y# (first author) , et al. Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Analysis of a multicenter, phase III randomized trial. Radiother Oncol. 2018;129(1):18-22.  

7. Liu X# ,... , Zhang Y* (corresponding author) . Differential benefit of induction chemotherapy according to body mass index in nasopharyngeal carcinoma – Pooled analysis of two randomized trials. Oral Oncol. 2022;125:105718. 

8. Zhang Y# (first author) , Zhang ZC# , Li WF, Liu X, Liu Q, Ma J * . Prognosis and staging of parotid lymph node metastasis in nasopharyngeal carcinoma: An analysis in 10,126 patients. Oral Oncol. 2019; 95:150-156.  

9. Li XM# , ..., Zhang Y* (joint corresponding author)  , Ma J * . The immune modulation effects of gemcitabine plus cisplatin induction chemotherapy in nasopharyngeal carcinoma. Cancer Med. 2022; 11(18):3437-3444.